An observational study in Hemophilia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 2 sites in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China — 11 open to participants now, 12 under way, none of them phase 3. Hemophilia A · Institute of Hematology & Blood Diseases Hospital, China.
Among the 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China, this one is one of 3 that started in 2026, is one of 4 observational ones, reaches primary completion later than 7 of the 11 other live ones, and was the 10th registered.
845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.
Browse Hemophilia A studies →11 of the 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 12–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+ · Men only
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 14–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–65 · Men only
By country, each count listing its studies:
Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 100 is above the median of 81 across 311 observational studies indexed under Hemophilia A.
Median enrollment 12 across the 9 interventional studies, 350 across the 4 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 414 studies on the registry; 292 are open to participants now.
5 of the studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05888870Institute of Hematology & Blood Diseases Hospital, ChinaITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor | 2026-12-01 |
| NCT07406139Institute of Hematology & Blood Diseases Hospital, ChinaPCC Treatment for Hemophilia Patients With Inhibitor(2022PCC-A) | 2026-12-20 |
| NCT05849740Institute of Hematology & Blood Diseases Hospital, ChinaAn Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A | 2027-04-30 |
| NCT06992076Institute of Hematology & Blood Diseases Hospital, ChinaAdult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry | 2027-08-31 |
| NCT07788469Institute of Hematology & Blood Diseases Hospital, ChinaA Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia A | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 13 studies in Hemophilia A by Institute of Hematology & Blood Diseases Hospital, China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Research Title:Adult and adolescent hemophilia patients treated with Marstacimab: a patient Experience Registry (AMBER) Protocol Number:94250855 Protocol Version Number:version 0.3 Date:15-November-2024 Leading site:Institution of Hematology \& Blood Diseases Hospital, Chinese Academy of Medical Sciences Active Pharmaceutical Ingredient:a human IgG1 monoclonal antibody that targets the tissue factor pathway inhibitor (TFPI) Drug Name Generic name: marstacimab-hncq Purpose of the Study Primary Objectives:To quantify patient preferences for subcutaneous versus intravenous (IV) injection using the Marstacimab-Patient Preference Questionnaire (M-PPQ) after 1 month of marstacimab for routine prophylaxis treatment.
To assess the treatment burden using the Hemophilia Treatment Experience Measure (Hemo-TEM) in hemophilia patients after 6 months of marstacimab for routine prophylaxis treatment.
Exploratory Objectives:
To evaluate the annualized bleeding rate (ABR) of different types of bleeds after 6 months of subcutaneous marstacimab injections in hemophilia patients.
To assess changes in joint status scores between baseline and the final visit after 6 months of subcutaneous marstacimab injections in hemophilia patients, using the Hemophilia Early Arthropathy Detection with Ultrasound in China (HEAD-US-C).
To evaluate patient preferences regarding treatment experience via M-PPQ after 6 months
patients with hemophilia who will receive marstacimab for routine prophylactic treatment in a real-world setting. Each patient will receive treatment and care according to the standard clinical practice. The total recruitment period will be 18 months. Patients will be prescribed marstacimab in routine practice and initiate marstacimab treatment on the same day (or as soon as possible after prescribing). The observation period for individual patients is defined as ending on the 180th day from the index date (the date of the first dose of marstacimab).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Participants with a diagnosis of hemophilia A or hemophilia B eligible to receive prophylaxis.
Clinical physicians prescribe marstacimab for routine prophylaxis treatment of hemophilia patients based on the actual conditions of the patients and in accordance with the approved indications of marstacimab.
Adolescent patients(12 to less than 18 years) and adult (18 years and older) patients.
Signed consent obtained before the study, participant or legally authorized representative, or participant's caregiver capable of giving signed .
Exclusion Criteria:
- Those who are unable to complete at least one month follow-up based on the investigator's judgment.
Severe impairment of speech, vision, memory or cognition that affects communication and ability to complete questionnaires and follow-up visits.
Women of childbearing age who plan to become pregnant within the next 2 months, as well as women who are pregnant or breastfeeding.
Patients are participating in other clinical trials. There are other conditions that the investigator deems unsuitable for participation in this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
the first visit (V1) is scheduled on the day of the first administration of marstacimab. The recommended dosing frequency for the patient should follow the instructions provided, which are as follows: On Day 1, administer 300 mg subcutaneously (divided into two injections, each 150 mg) (loading dose); starting from Day 8, administer 150 mg subcutaneously once a week. Record the patient's prescription recommendations, actual treatment records (administration time, dosage, frequency), and adherence rates. Visit 2 (V2) and visit 3 (V3) are defined as 30 days (±7 days) and 180 days (±30 days) after the initiation of marstacimab treatment, respectively.
patient preferences for subcutaneous
To quantify patient preferences for subcutaneous versus intravenous (IV) injection using the Marstacimab-Patient Preference Questionnaire (M-PPQ) after 1 month of marstacimab for routine prophylaxis treatment.
Time frame: after 1 month of marstacimab treatment
To assess the treatment burden
To assess the treatment burden using the Hemophilia Treatment Experience Measure (Hemo-TEM) in hemophilia patients after 6 months of marstacimab for routine prophylaxis treatment.
Time frame: after 6 month of marstacimab treatment
To evaluate the annualized bleeding rate (ABR)
To evaluate the annualized bleeding rate (ABR) of different types of bleeds after 6 months of subcutaneous marstacimab injections in hemophilia patients.
Time frame: after 6 month of marstacimab treatment
To assess changes in joint status scores
To assess changes in joint status scores between baseline and the final visit after 6 months of subcutaneous marstacimab injections in hemophilia patients, using the Hemophilia Early Arthropathy Detection with Ultrasound in China(HEAD-US-C).
Time frame: after 6 month of marstacimab treatment
patient preferences for subcutaneous
To evaluate patient preferences regarding treatment experience via M-PPQ after 6 months.
Time frame: after 6 month of marstacimab treatment
Plan to share: No — Patient-level variables including demographics, clinical characteristics, treatment history will be extracted from medical records. Patient-reported outcomes (PROs), namely the M-PPQ and Hemo-TEM questionnaires, will be reported by patients. Clinician-reported outcomes (ClinROs), namely the HEAD-US-C scale, will be reported by clinicians who have undergone training and certification. Electronic case report forms (eCRFs) will be prepared for all data collection fields.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Aug 2027, 18 months after the start.
Of 78 non-industry observational studies under Hemophilia A, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 96. This study's planned 18 months is below that.
Counting every sponsor, half of 131 studies reached it within 45 months; a quarter within 25 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute of Hematology & Blood Diseases Hospital, China →